RevolKa Reimagines Antibody Engineering with "RevoAb®"

A Same-day Sequence Optimization Service to Elevate Antibody Expression Levels by RevolKa’s advanced AI Protein Engineering Engine

SENDAI, Japan--(BUSINESS WIRE)--RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein^®, is pleased to announce the official global launch of RevoAb^®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibody yields.

RevoAb^®: The Next-Gen AI Antibody Design

Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb^® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb^® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allows researchers worldwide to experience RevolKa’s high-performance antibody design.

Key Advantages of RevoAb^®

• Speed: Multiple optimized sequence candidates for improved physicochemical properties in a day, not weeks
• Satisfaction: Proven records, 92% success rate, by Japanese pharmaceutical and academic customers (including internal data), particularly with significant improvements in protein expression levels during the pre-launch period beginning July 2025
• Low cost: Starting at $700 USD per antibody for exploring physicochemical property improvements, “Start with RevoAb^®, Scale with aiProtein^® , high-value, fully customized AI antibody engineering”
• ZERO Complex AI Configurations: No specialized AI and bioinformatics expertise and expert-level AI parameter tuning, making advanced AI design accessible to every researcher
• High Modality and Species Compatibility: Wide-Range of antibody modalities, from monoclonal IgG to the next-gen antibodies, such as variable fragment formats (Fv, VHH) across diverse species including human, mouse, rat, rabbit, chicken, llama, etc.

For details, visit the RevoAb^® Service Site: https://revoab.revolka.com/en/

Proven Success in Japan

Throughout the pilot phase, RevoAb^® has successfully contributed to solving critical challenges for Japanese pharmaceutical companies, biotech ventures, and universities. The service has earned a strong reputation for its ability, for example, to overcome production issues. An example is shown below. One of the three RevoAb generated sequences of a difficult-to-express single chain Fv showed 7x higher expression levels in E.coli without serious change in affinity.

Background: Minimizing Lead Time and R&D Costs

Antibodies are essential across various industries, from therapeutics to diagnostics. However, optimizing their characteristics, such as stability, affinity, and productivity, remains a significant technical hurdle requiring substantial time and investment.

RevolKa helps to break these barriers by providing researchers worldwide with direct, simple access to the power of aiProtein^®. By streamlining the design process, RevoAb^® empowers scientists to focus on breakthrough discoveries.

About RevolKa Ltd.

RevolKa is a biotechnology company specialized in protein engineering using its proprietary AI platform, aiProtein^®. The company is committed to accelerating the development of novel biologics and industrial enzymes to improve human health and sustainability.